Clinical Trial Update: A Database Study to Estimate the Risk of Multiple Sclerosis Following Vaccination With Arepanrix™ in Manitoba, Canada

View source ↗

Summary

A completed database study estimates the risk of developing multiple sclerosis following Arepanrix™ vaccination in Manitoba, Canada.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Arepanrix (Influenza vaccine (H1N1))

Snippet

Sponsor: University of Manitoba | Conditions: Multiple Sclerosis | Status: COMPLETED